20 May 2013
Keywords: roche, refiles, dossier, tamiflu, eu, partner, gilead
Article | 28 February 2001
Roche and partner Gilead Sciences have resubmitted an approval dossierfor their orally-active neuraminidase inhibitor Tamiflu (oseltamivir phosphate) in the European ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.